by RAJ CHOVATIYA, MD, PHD, MSCI*; MEREDITH TYREE POLASKEY, MS*; EDWARD LAIN, MD; TODD SCHLESINGER, MD;

HEATHER WOOLERY-LLLOYD, MD; PATRICK BURNETT, MD; and DIANE HANNA, DNP

*Dr. Chovatiya and Ms. Polaskey share co- rst authorship of this article. DR.Chovatiya is a Clinical Associate Professor at the Rosalind Franklin University of Chicago Medical School and is the Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, Illinois. Ms. Polaskey is with the Department of Dermatology at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. Lain is with Sanova Dermatology and the Austin Institute for Clinical Research in Austin, Texas. Dr. Schlesinger is with the Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas in Charleston, South Carolina. Dr. Woolery-Llloyd is with Dr. Phillip Frost's Department of Dermatology and Cutaneous Surgery at University of Miami's Miller School of Medicine in Miami, Florida. Drs. Hanna and Burnett are with Arcutis Biotherapeutics, Inc. in Westlake Village, California.

J Clin Aesthet Dermatol. 2024;17(5):30–33.

Seborrheic dermatitis (SD) is a chronic inflammatory skin condition that commonly involves the scalp, and thus, affects a diverse demographic with varying hair care needs. Current SD treatments are limited based on optimized formulation, e cacy, adverse events, and lack of placebo-controlled trials. A novel roflumilast foam formulation has emerged as a promising therapeutic option optimally designed for use on the scalp and other hair-bearing areas. We conducted a comprehensive assessment of beauty industry standards, con rming the foam formulation's alignment with industry guidelines and exclusion of potentially harmful ingredients. In addition, consultation with an expert dermatologist panel yielded a strong endorsement, underscoring a high level of con dence in prescribing the foam across diverse hair and skin types.

KEYWORDS: Seborrheic dermatitis

FUNDING: No funding was provided for this article.

DISCLOSURES: Drs. Hanna and Burnett are employees of Arcutis Biotherapeutics, Inc. EL has served as an investigator, advisor, consultant, and/or speaker for AbbVie, Eli Lilly and Company, Bristol Myers Squibb, Ortho Dermatologics, P zer Inc, Sano , Regeneron, Galderma, Dermavant, Incyte, UCB, and Journey. Dr. Schlesinger has served as a consultant, speaker and/ or investigator for AbbVie, Arcutis, Boehringer-Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Eli Lilly and Company, Galderma, Janssen, Novartis, P zer Inc., UCB. Dr. Woolery-Llloyd has served as a consultant, speaker, and/or investigator for Ortho Dermatologics, L’Oréal, Eli Lillly and Company, Incyte, P zer Inc., Galderma, Allergan, Arcutis, Vyne, Eirion, and Regeneron Dr. Chovatiya has served as an advisory board member, consultant, and/or investigator for AbbVie, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, Incyte, Janssen, LEO Pharma, L’Oréal, Nektar Therapeutics, Novan, Inc., Opsidio, P zer Inc., Regeneron, RAPT, Sano , and UCB. Dr. Polaskey has no conflicts of interest relevant to this article.

CORRESPONDENCE: Raj Chovatiya, MD, PhD, MSCI; Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

Allison Garlet 1 , Valerie Andre-Frei 2 , Nicolas Del Bene 1 , Hunter James Cameron 3 , Anita Samuga 3 , Vimal Rawat 4 , Philipp Ternes 5 and Sabrina Leoty-Okombi 2,*

1 BASF Corporation, 540 White Plains Road, Tarrytown, NY 10591, USA; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (A.G.); 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (N.D.B.)

2 BASF Beauty Care Solutions, 32 Rue Saint Jean de Dieu, 69007 Lyon, France; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

3 BASF Corporation, 26 Davis Dr, Raleigh-Durham, NC 27709, USA; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (H.J.C.); 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (A.S.)

4 BASF SE, Speyerer Str. 2, 67117 Limburgerhof, Germany; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

5 BASF Metabolome Solutions GmbH, Tegeler Weg 33, 10589 Berlin, Germany; 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

* Correspondence: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

Citation: Garlet, A.; Andre-Frei, V.;

Del Bene, N.; Cameron, H.J.; Samuga,

A.; Rawat, V.; Ternes, P.; Leoty

Okombi, S. Facial Skin Microbiome

Composition and Functional Shift

with Aging. Microorganisms 2024, 12,

1021. https://doi.org/10.3390/

microorganisms12051021

Academic Editors: Paul D. Facey

and Claire Morgan

Received: 30 January 2024

Revised: 14 May 2024

Accepted: 16 May 2024

Published: 18 May 2024

Abstract: The change in the skin microbiome as individuals age is only partially known. To provide a better understanding of the impact of aging, whole-genome sequencing analysis was performed on facial skin swabs of 100 healthy female Caucasian volunteers grouped by age and wrinkle grade. Volunteers’ metadata were collected through questionnaires and non-invasive biophysical measurements. A simple model and a biological statistical model were used to show the difference in skin microbiota composition between the two age groups. Taxonomic and non-metric multidimensional scaling analysis showed that the skin microbiome was more diverse in the older group (≥55 yo). There was also a significant decrease in Actinobacteria, namely in Cutibacterium acnes, and an increase in Corynebacterium kroppenstedtii. Some Streptococcus and Staphylococcus species belonging to the Firmicutes phylum and species belonging to the Proteobacteria phylum increased. In the 18–35 yo younger group, the microbiome was characterized by a significantly higher proportion of Cutibacterium acnes and Lactobacillus, most strikingly, Lactobacillus crispatus. The functional analysis using GO terms revealed that the young group has a higher significant expression of genes involved in biological and metabolic processes and in innate skin microbiome protection. The better comprehension of age-related impacts observed will later support the investigation of skin microbiome implications in antiaging protection.

Keywords: skin aging; skin microbiome; gene ontology; diversity; L. crispatus; C. acnes; C. kroppenstedtii

Kyong Kim a , Eun-Young Park b , Dong-Jae Baek b , Chang-Seok Lee c , Yoon Sin Oh a,*

a Department of Food and Nutrition, Eulji University, Seongnam, South Korea

b College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Jeonnam, South Korea

c Department of Beauty and Cosmetic Science, Eulji University, Seongnam, South Korea

ARTICLE INFO

Keywords: Allomyrina dichotoma larvae Ultraviolet B Photo-aging Human dermal fibroblast  Collagen

ABSTRACT

Skin aging is affected by a variety of factors, including ultraviolet rays, oxidative stress, medications, smoking, and genetics. Among them, photo-aging accounts for about 80% of skin aging. The present study was evaluated to verify the potential of Allomyrina dichotoma larvae, which has recently been attracting attention as an edible insect, as an anti-aging substance. UVB irradiation at 100 mJ/cm2 was sufficient to induce photo-aging of fibroblasts within 24 h, which was alleviated after treatment with 70% ethanol extract of Allomyrina dichotoma larvae extract (ADLE). To obtain an extract from ADLE, which has a relatively high content of polyphenol compounds containing physiological activity, fractional solvent extraction was carried out using organic solvents such as hexane, chloroform, ethyl acetate, and butanol. Additionally, ethyl acetate and butanol fractions contributed to the inhibition of UVB-induced ROS production, cell damage, and senescence of fibroblasts. It was also confirmed that the two fractions can regulate the expression of MMP-1 and AP-1. In particular, the ethyl acetate fraction showed an excellent effect in recovering collagen decomposed by UVB. Therefore, these results suggest that ADLE has potential as a natural insect-derived biomaterial to inhibit UVB-induced photo-aging.

Seo Hyeong Kim1 Ji Hye Kim1 Yoon Mi Choi1 Su Min Seo1 Eun Young Jang1 Sung Jae Lee1 Suhyun Cho2 Do Hyeon Jeong3 Kwang Hoon Lee1

1 Cutis Biomedical Research Center Co. Ltd., Seoul, Republic of Korea

2 Yonsei BB Skin Clinic, Seoul, Republic of Korea

3 Raphas Co. Ltd., Seoul, Republic of Korea

Correspondence

Kwang Hoon Lee, Cutis Biomedical Research Center Co. Ltd., (07327) 5F, 97, Uisadang-daero, Yeongdeungpo-gu, Seoul, Republic of Korea.

Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

Abstract

Background: Current methods for evaluating efficacy of cosmetics have limitations because they cannot accurately measure changes in the dermis. Skin sampling using microneedles allows identification of skin-type biomarkers, monitoring treatment for skin inflammatory diseases, and evaluating efficacy of anti-aging and anti-pigmentation products.

Materials and methods: Two studies were conducted: First, 20 participants received anti-aging treatment; second, 20 participants received anti-pigmentation treatment. Non-invasive devices measured skin aging (using high-resolution 3D-imaging in the anti-aging study) or pigmentation (using spectrophotometry in the anti-pigmentation study) at weeks 0 and 4, and adverse skin reactions were monitored. Skin samples were collected with biocompatible microneedle patches. Changes in expression of biomarkers for skin aging and pigmentation were analyzed using qRT-PCR.

Results: No adverse events were reported. In the anti-aging study, after 4 weeks, skin roughness significantly improved in 17 out of 20 participants. qRT-PCR showed significantly increased expression of skin-aging related biomarkers: PINK1 in 16/20 participants, COL1A1 in 17/20 participants, and MSN in 16/20 participants. In the anti-pigmentation study, after 4 weeks, skin lightness significantly improved in 16/20 participants. qRT-PCR showed significantly increased expression of skinpigmentation-related biomarkers: SOD1 in 15/20 participants and Vitamin D Receptor (VDR) in 15/20 participants. No significant change in TFAP2A was observed.

Conclusion: Skin sampling and mRNA analysis for biomarkers provides a novel, objective, quantitative method for measuring changes in the dermis and evaluating the efficacy of cosmetics. This approach complements existing evaluation methods and has potential application in assessing the effectiveness of medical devices, medications, cosmeceuticals, healthy foods, and beauty devices.

KEYWORDS

in vivo efficacy test, skin aging, skin biomarkers, skin pigmentation